Cereno Scientific’s abstract on CS1’s innovative Phase II study design accepted at top pulmonary vascular congress PVRI held in June, 2022
Cereno Scientific (XSAT: CRNO B) today announced that an abstract regarding the innovative design of the Phase II study with drug candidate CS1 in pulmonary arterial hypertension (PAH) has been accepted as a poster presentation at the 15th Annual World Congress on Pulmonary Vascular Disease in Athens, Greece, on June 22-26, 2022. The abstract is a collaboration between Cereno, Dr. Raymond Benza, global PAH key opinion leader and principal investigator (PI) for the Phase II study and study collaborator Abbott.
The abstract with the title “Investigation of efficacy, safety and optimal dose of CS1 in subjects with pulmonary arterial hypertension: a prospective, randomized, multicenter, parallel-group phase II study” was submitted to the congress by the Phase II study’s PI Dr. Raymond Benza. The abstract authors are Dr. Raymond Benza Professor of Medicine at Wexner Medical Center, Ohio State University, Niklas Bergh CSO at Cereno, Philip Adamson CMO for the Heart Failure Division at global healthcare company Abbott and Björn Dahlöf CMO at Cereno. The abstract will be presented as a poster by Dr. Raymond Benza.
The congress organizer is the Pulmonary Vascular Research Institute (PVRI), a charity that brings together the best medical professionals in the world who have an interest in pulmonary hypertension or pulmonary vascular disease. PVRI facilitates global research and development of medicines for the treatment of pulmonary hypertension and other pulmonary vascular diseases. Attendees at the PVRI World Congress includes medical professionals, drug regulatory bodies and professionals from the pharmaceutical industry.
The abstract will be published in conjunction with the start of the congress on June 22, 2022.
Drug candidate CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator. The candidate’s pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties are all relevant for PAH, an incurable, progressive disease with a significant unmet need for therapies that treat the underlying pathophysiology with improved safety, tolerability and efficacy profiles. The aim of the ongoing Phase II study is to evaluate CS1’s safety, tolerability, and exploratory efficacy in PAH. The study is run in collaboration with global healthcare company Abbott who is providing the cutting-edge CardioMEMS HF System for continuous monitoring of patients’ pulmonary pressure.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Targeted at treating cardiovascular disease, drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist and drug candidate CS014 is an HDAC inhibitor with epigenetic effects. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.